The pharmaceutical industry will need to outsource even more pharma manufacturing to keep up with the speed of the developments surrounding Covid-19 vaccines and drugs, says GlobalData, a data and analytics company.
The company’s report, “Covid-19: Contract Pharmaceutical Development and Manufacturing Relationships”, mentions that the coming changes, such as the approval of Covid vaccines in pediatric populations, and the administering of extra (or “booster”’) doses, will increase the manufacturing demand exceeding billions of doses that are already contracted. In order to generate these high volumes and keep up with the demand, pharma will need to call upon contract manufacturing organizations (CMOs), increasing the amount of existing vaccine contracts and creating new ones.
Currently, there are more than 1,000 vaccines and therapies in development for Covid-19, and over 30 have been approved (or granted emergency use authorization) for the virus. According to GlobalData, hundreds of manufacturing agreements have been publicly disclosed to date between Covid-19 vaccine and therapy developers and CMOs.